From the Center for Translational Medicine (V.N.S.G., R.K.).
Lewis Katz School of Medicine, Temple University, Philadelphia, PA; Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta (F.S.-T., M.E.D.).
Circ Res. 2018 Jul 6;123(2):188-204. doi: 10.1161/CIRCRESAHA.117.311215.
Recent literature suggests that extracellular vesicles (EVs), secreted from most cells and containing cell-specific cargo of proteins, lipids, and nucleic acids, are major driver of intracellular communication in normal physiology and pathological conditions. The recent evidence on stem/progenitor cell EVs as potential therapeutic modality mimicking their parental cell function is exciting because EVs could possibly be used as a surrogate for the stem cell-based therapy, and this regimen may overcome certain roadblocks identified with the use of stem/progenitor cell themselves. This review provides a comprehensive update on our understanding on the role of EVs in cardiac repair and emphasizes the applications of stem/progenitor cell-derived EVs as therapeutics and discusses the current challenges associated with the EV therapy.
最近的文献表明，细胞外囊泡（EVs）由大多数细胞分泌，包含蛋白质、脂质和核酸等细胞特异性货物，是正常生理和病理条件下细胞内通讯的主要驱动因素。最近关于干细胞/祖细胞 EVs 作为潜在治疗方式的证据令人兴奋，因为 EVs 可以作为基于干细胞治疗的替代物，并且这种方案可能克服了使用干细胞/祖细胞本身所遇到的某些障碍。本文综述了我们对 EV 在心脏修复中的作用的理解，并强调了干细胞/祖细胞衍生的 EVs 在治疗中的应用，同时讨论了与 EV 治疗相关的当前挑战。
